Načítá se...
Ibrutinib: a first in class covalent inhibitor of Bruton’s tyrosine kinase
Ibrutinib (formerly PCI-32765) is a potent, covalent inhibitor of Bruton’s tyrosine kinase, a kinase downstream of the B-cell receptor that is critical for B-cell survival and proliferation. In preclinical studies, ibrutinib bound to Bruton’s tyrosine kinase with high affinity, leading to inhibition...
Uloženo v:
| Vydáno v: | Future Oncol |
|---|---|
| Hlavní autoři: | , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
2014
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4632638/ https://ncbi.nlm.nih.gov/pubmed/24941982 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2217/fon.14.51 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|